![](/img/cover-not-exists.png)
Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with HCV genotype 2, 4, 5, or 6 infection: the C-SCAPE study
Brown, A., Hézode, C., Zuckerman, E., Foster, G. R., Zekry, A., Roberts, S. K., Lahser, F., Durkan, C., Badshah, C., Zhang, B., Robertson, M., Wahl, J., Barr, E., Haber, B.Language:
english
Journal:
Journal of Viral Hepatitis
DOI:
10.1111/jvh.12801
Date:
November, 2017
File:
PDF, 733 KB
english, 2017